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OBJECTIVE: Restless legs syndrome (RLS) is a neurological dis-
order characterised by unpleasant sensations in the legs and an
irresistible urge to move the legs to relieve the discomfort. This
study aims to describe the drug treatment patterns amongst UK
RLS patients during a 12-month period; in this period pharma-
cological therapy was based on “off-label” use of medication.
METHODS: A data base capturing nationally representative
prescribing for patients presenting in general practice (DIN-
LINK) was used to describe treatments received by patients with
a diagnosis of RLS presenting to a GP in the 12 months up to
31st March 2005 (n = 556). This data base covers a population
of about 800,000 patients and about 400 GPs. RESULTS: Annu-
ally, the number of patients with RLS for which they were receiv-
ing drug treatment was estimated to be up to 46 per 100,000
catchment population (up to 66% of the 70 per 100,000 patients
with RLS who annually make contact with a GP). Drug treat-
ments included the following (the percentages of patients receiv-
ing the different types of drug treatments are shown in brackets):
antidepressants (20% of whom 71% received amitriptyline),
anticonvulsants (18% of whom 76% received clonazepam),
quinine (13%), non-narcotic analgesia (13%), dopamine ago-
nists (5%), hypnotics (6%), tranquilisers (4%) NSAIDs (3%)
and L-dopa (4%). CONCLUSIONS: The substantial percentage
of patients receiving some form of analgesia or treatment for
insomnia may be a reﬂection of the limited success of existing
patterns of treatment in controlling symptoms (presumably, clon-
azepam in line with UK guidelines, was used mostly for insom-
nia). A large proportion of RLS patients were given amitriptyline
which can worsen RLS and quinine, a treatment effective only
when cramps co-exist.
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OBJECTIVES: ISPR is a prospective, post-market, surveillance
registry designed to monitor implantable neurological devices.
For each patient enrolled demographics, implant and practice
techniques, and patient reported outcomes are collected and ana-
lyzed to elucidate the etiology of device complications. The goal
is to expand registry centers, based on pre-deﬁned criteria, and
generate data representative of the medical community and its
patients. This registry is a foundation and electronic platform for
outcome registry projects. METHODS: Single and multi-physi-
cian centers follow standard clinical practice and a common reg-
istry protocol. Center activation includes software and protocol
training and IRB approval at each center. Information registered
with the U.S Food and Drug and Administration (FDA) man-
dated Device Registration System (DRS) pre-populates the reg-
istry avoiding redundant data submission, while centers provide
additional information through electronic data capture. Active
surveillance occurs at 6-month intervals with data reporting
required for device or patient events. These event data are elec-
tronically communicated to fulﬁll FDA-mandated event report-
ing regulations, thus creating efﬁciencies for the sponsor and
physician. The potential of selection bias in ISPR is minimized
through 100% eligibility of all implanted devices at each center.
The approach for ISPR center expansion is based on geographic,
specialty, and practice distribution to achieve a representative
sampling of real world experience, effectiveness and safety. A
multidisciplinary advisory board oversees reporting with the goal
of peer reviewed scientiﬁc presentation and publication.
RESULTS: Annual aggregate and center speciﬁc reports are gen-
erated including descriptive statistics and survival curves. CON-
CLSUIONS: The data collected in this registry are representative
of the medical community with generalizability to a broader
patient population. ISPR results may illuminate methods to
improve therapy and guide development, provide insight into the
etiology of events through evaluation beyond what is possible
with passive surveillance, and generate best practices associated
with reduced events and improved outcomes.
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OBJECTIVES: To measure frequency and intensity of diabetic
peripheral neuropathy (DPN) symptoms a 6 item scale was
developed in US English for health care professionals (HCP): the
Neuropathy Total Symptom Score-6 (NTSS-6). Prior to use in an
international study a self-administered (SA) version was devel-
oped and translated into 9 languages. METHODS: The devel-
opment of the SA version involved the establishment of patient
instructions and the comprehension test on 5 US patients with
DPN and 2 diabetologists. The following translation process was
conducted by a specialist in each target country: (1) two forward
translations; (2) back translation; (3) review by a clinician; (4)
comprehension test on 5 subjects with DPN and (5) international
harmonisation. Where translations of the HCP version existed,
an SA version was developed and the accuracy of the transla-
tions checked. RESULTS: The ﬁrst challenge was maintaining
conceptual equivalence between the HCP and SA versions. The
development of the SA version required patients’ understanding
the meaning of the explored symptoms and their level of sever-
ity without clariﬁcation by HCPs. The second challenge was
ﬁnding conceptually equivalent and culturally relevant expres-
sions of the different types of pain. In some instances literal
equivalents for the original symptom existed, but according to
patients did not correspond to the original concept. In other
cases the original did not have a literal equivalent and had to be
paraphrased. CONCLUSIONS: The 9 languages of the NTSS-6
SA were established according to a rigorous development and
translation process to ensure conceptual equivalence and cultural
relevance across languages and ultimately the international com-
parison and pooling of data. Issues encountered during this
process support the advantage of integrating international feed-
back on concepts and wording before ﬁnalizing a scale.
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Different surgical procedures are described to improve hand-
function in tetraplegie either with or without implantation of an
8-channel electrical stimulator. Clinical experience shows that
patients are not always willing to accept these devices despite
their severe functional limitations. This can be explained because
the offered treatment is too demanding. For future clinical appli-
cations and for further technical developments it is necessary to
obtain more insight into the factors that determine willingness
to accept assistive technology. OBJECTIVES: To determine the
